AstraZeneca: UK Investment Paused Despite New Drug Pricing Deal | Business News

Despite a recent agreement between the UK and US governments aimed at improving pharmaceutical pricing, AstraZeneca, Britain’s largest pharmaceutical company, appears unlikely to revive a paused September investment in a Cambridge research hub. The deal, reached in December, is viewed by AstraZeneca’s chief executive, Pascal Soriot, as a “very positive step” but “probably will not be sufficient” to restart the £200m project.

The pause in investment reflects a broader trend of pharmaceutical companies reconsidering their commitment to the UK, citing concerns over drug pricing and access to markets. AstraZeneca previously scrapped a £450m expansion of its vaccine manufacturing site in Speke, near Liverpool, last year, citing cuts in state funding. These decisions underscore a growing frustration within the industry regarding the perceived challenges of operating and investing in the UK.

The recent UK-US agreement sought to address longstanding pressure from the US for lower drug prices, which traditionally have been significantly higher there than in other countries. The agreement aims to create a more balanced pharmaceutical ecosystem, but Soriot suggests that its impact on incentivizing investment in innovative research and development within the UK remains uncertain. He emphasized that the practical implementation of the deal needs to be carefully considered.

AstraZeneca’s strategic focus is increasingly shifting towards other markets, notably the US and China. The company recently announced a $15bn (approximately £11bn) investment in China, its second-largest market, and is also committing $50bn to US factories and labs by 2030. The company also listed its shares in New York in February, while maintaining its primary listing in London.

The core of the issue lies in the complex relationship between pharmaceutical companies and the National Health Service (NHS) in the UK. A long-running dispute exists over drug pricing and the availability of new medicines on the NHS. The National Institute for Health and Care Excellence (NICE), the body responsible for assessing the cost-effectiveness of new medicines, has, for example, not recommended AstraZeneca’s breast cancer infusion, Enhertu, for use in England and Wales.

Soriot highlighted the inherent risks associated with pharmaceutical research and development, noting that many drugs fail during the clinical trial process. He argued that this risk and the associated costs “has to be recognised,” implying a need for a more supportive pricing and regulatory environment to encourage continued investment in innovation.

Despite these challenges, Soriot reiterated AstraZeneca’s commitment to the UK. However, the company’s actions – pausing investments and shifting focus to other markets – suggest that commitment is contingent on a more favorable business climate. The UK-US drug pricing deal, while a step in the right direction, appears insufficient to fully address the concerns of AstraZeneca and other pharmaceutical giants.

AstraZeneca forecasts steady sales and profit growth this year, aiming to reach $80bn in annual sales by 2030. The company reported an 8% increase in sales to $58.7bn last year, with profits up 11%. Sales in the fourth quarter of last year reached a record $15.5bn, a 2% increase. Cancer drug sales rose significantly (20%) to $7bn, while cardiovascular product revenues declined by 6% due to generic competition.

Currently, AstraZeneca has 16 blockbuster medicines – those generating over $1bn in annual sales – and aims to increase that number to 25 by 2030. The company is currently conducting over 100 late-stage clinical trials and anticipates releasing results from more than 20 of them this year, signaling a continued commitment to research and development despite the current uncertainties surrounding its UK investments.